Log In
BCIQ
Print this Print this
 

rAAV2/2_ND4 (GS010)

  Manage Alerts
Collapse Summary General Information
Company GenSight Biologics S.A.
DescriptionGene therapy product containing the human ND4 gene
Molecular Target NADH dehydrogenase subunit 4 (ND4)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase III
Standard IndicationOptic neuropathy
Indication DetailsTreat Leber's hereditary optic neuropathy (LHON)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today